Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 25Unknown 20Terminated 3Active not recruiting 1

Sponsor Class

OTHER 8NIH 3INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1Breast 1

Conditions

Lymphoma, Follicular 1Carcinoma, Renal Cell 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Cyclophosphamide 47aldesleukin 30fludarabine phosphate 26fludarabine 24Carboplatin 18Rituximab 16Interleukin-2 16Cisplatin 16Bevacizumab 162,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 16Radiotherapy 15Paclitaxel 15Magnetic Resonance Spectroscopy 14Bortezomib 14Filgrastim 13Doxorubicin 13Oxaliplatin 12Erlotinib Hydrochloride 12Trastuzumab 11Leucovorin 11Etoposide 11Biopsy 11Taxes 10Radiation 10Fluorouracil 10alvocidib 9Specimen Handling 9Sorafenib 9Docetaxel 9Dexamethasone 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × NIH × Interferon-alpha × Clear all
NCT00095862 2018-02-05

Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers

National Cancer Institute (NCI)

Phase 1/2 Terminated
24 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00098618 2013-07-02

Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
40 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00015912 2013-01-25

Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
35 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡